$TCRT
Alaunos Therapeutics, Inc.

2016 Q3 Form 10-Q Financial Statement

#000119312516676724 Filed on August 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $1.600M $1.700M $270.0K
YoY Change -14.44% 529.63% 35.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.540M $3.710M $7.070M
YoY Change 15.31% -47.52% 133.33%
% of Gross Profit
Research & Development $8.975M $129.2M $7.424M
YoY Change -47.11% 1640.68% -11.05%
% of Gross Profit
Depreciation & Amortization $70.00K $90.00K $120.0K
YoY Change 16.67% -25.0% 20.0%
% of Gross Profit
Operating Expenses $8.975M $129.2M $7.424M
YoY Change -47.11% 1640.68% -11.05%
Operating Profit -$10.91M -$131.2M -$14.23M
YoY Change -39.92% 822.62% 27.27%
Interest Expense $20.00K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $39.00K $42.00K $14.00K
YoY Change -1075.0% 200.0% 1300.0%
Pretax Income -$10.85M -$131.2M -$14.21M
YoY Change -40.29% 823.29% 154.66%
Income Tax
% Of Pretax Income
Net Earnings -$14.45M -$131.2M -$14.21M
YoY Change -20.5% 823.23% 154.86%
Net Earnings / Revenue -902.81% -7717.65% -5263.33%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.11 -$1.01 -$0.11
COMMON SHARES
Basic Shares Outstanding 131.7M shares 131.8M shares 128.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.70M $109.0M $118.6M
YoY Change -42.19% -8.09% 123.77%
Cash & Equivalents $94.68M $109.0M $118.6M
Short-Term Investments
Other Short-Term Assets $21.00M $17.70M $4.400M
YoY Change 153.01% 302.27% 340.0%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $100.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $115.7M $126.7M $123.1M
YoY Change -32.93% 2.95% 127.82%
LONG-TERM ASSETS
Property, Plant & Equipment $825.0K $682.0K $321.0K
YoY Change 214.89% 112.46% -53.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $492.0K $493.0K $509.0K
YoY Change 0.2% -3.14% -0.78%
Total Long-Term Assets $1.445M $1.303M $958.0K
YoY Change 64.02% 36.01% -27.64%
TOTAL ASSETS
Total Short-Term Assets $115.7M $126.7M $123.1M
Total Long-Term Assets $1.445M $1.303M $958.0K
Total Assets $117.1M $128.0M $124.0M
YoY Change -32.44% 3.2% 124.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.814M $2.031M $3.143M
YoY Change -56.33% -35.38% 603.13%
Accrued Expenses $7.364M $7.392M $8.752M
YoY Change -59.4% -15.54% 12.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.74M $16.04M $13.11M
YoY Change -46.86% 22.31% 21.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $119.0M $0.00
YoY Change
Other Long-Term Liabilities $44.00M $44.90M $17.00K
YoY Change -11.82% 264017.65% -15.0%
Total Long-Term Liabilities $44.00M $163.9M $17.00K
YoY Change -11.82% 964017.65% -15.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.74M $16.04M $13.11M
Total Long-Term Liabilities $44.00M $163.9M $17.00K
Total Liabilities $59.73M $180.0M $13.60M
YoY Change -24.89% 1223.84% -22.88%
SHAREHOLDERS EQUITY
Retained Earnings -$646.8M -$635.9M -$465.1M
YoY Change 33.85% 36.74% 30.59%
Common Stock $582.4M $583.9M $575.5M
YoY Change 0.92% 1.47% 47.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$64.42M -$51.99M $110.4M
YoY Change
Total Liabilities & Shareholders Equity $117.1M $128.0M $124.0M
YoY Change -32.44% 3.2% 124.11%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$14.45M -$131.2M -$14.21M
YoY Change -20.5% 823.23% 154.86%
Depreciation, Depletion And Amortization $70.00K $90.00K $120.0K
YoY Change 16.67% -25.0% 20.0%
Cash From Operating Activities -$14.11M -$15.07M -$11.69M
YoY Change -131.22% 28.91% 53.01%
INVESTING ACTIVITIES
Capital Expenditures $210.0K $100.0K $0.00
YoY Change 2000.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$210.0K -$100.0K $0.00
YoY Change 2000.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -670.0K 560.0K
YoY Change -100.0% -219.64% 60.0%
NET CHANGE
Cash From Operating Activities -14.11M -15.07M -11.69M
Cash From Investing Activities -210.0K -100.0K 0.000
Cash From Financing Activities 0.000 -670.0K 560.0K
Net Change In Cash -14.32M -15.84M -11.13M
YoY Change -131.63% 42.32% 50.61%
FREE CASH FLOW
Cash From Operating Activities -$14.11M -$15.07M -$11.69M
Capital Expenditures $210.0K $100.0K $0.00
Free Cash Flow -$14.32M -$15.17M -$11.69M
YoY Change -131.69% 29.77% 51.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
131732423 shares
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118550000
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131732423 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2642596 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3353760 shares
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131732423 shares
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2237935 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.08
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3438103 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.08
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
5.08
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-635919000
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q2 us-gaap Liabilities
Liabilities
180002000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128012000
CY2016Q2 us-gaap Deferred Rent Credit
DeferredRentCredit
423000
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2031000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
-51990000
CY2016Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
44722000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
132000
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
583797000
CY2016Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
200000
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
16035000
CY2016Q2 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
119045000
CY2016Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
223000
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7392000
CY2016Q2 us-gaap Assets Current
AssetsCurrent
126709000
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
682000
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3430000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109004000
CY2016Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2016Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
15000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
3947000
CY2016Q2 us-gaap Assets
Assets
128012000
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
493000
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
17690000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4046000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42803000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131718579 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131718579 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2120834 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.24
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3481469 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.96
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-492700000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Liabilities
Liabilities
66353000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153724000
CY2015Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
661000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6861000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2008000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
87371000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
47917000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
132000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
579939000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
313000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18123000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
348000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8906000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
152521000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
581000
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8622000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140717000
CY2015Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2015Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
446000
CY2015Q4 us-gaap Assets
Assets
153724000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
494000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11358000
CY2015Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15 million and no greater than $20 million per year.
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4666848 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21411000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.59
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
120953279 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
51800 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
34000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
18000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
us-gaap Contracts Revenue
ContractsRevenue
544000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.81
us-gaap Operating Income Loss
OperatingIncomeLoss
-92452000
us-gaap Net Income Loss
NetIncomeLoss
-92442000
us-gaap Interest Paid
InterestPaid
0
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
246000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Stock Issued1
StockIssued1
67285000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3302000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-55000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1138000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
19000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
67285000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-22000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
94320000
us-gaap Share Based Compensation
ShareBasedCompensation
4577000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
236000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-544000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
17000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11323000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1569000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
97180000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
477000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
92996000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81673000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
75747000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3140000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4674491 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-31152000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M
dei Trading Symbol
TradingSymbol
ZIOP
dei Amendment Flag
AmendmentFlag
false
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M16D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
10366 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.62
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.48
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.13
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130271806 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
169000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.10
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
136000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y8M16D
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
257000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
119045000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1000
us-gaap Contracts Revenue
ContractsRevenue
3666000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
87000
us-gaap Operating Income Loss
OperatingIncomeLoss
-143282000
us-gaap Net Income Loss
NetIncomeLoss
-143219000
us-gaap Interest Paid
InterestPaid
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4075000
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
853000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
551000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
63000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6332000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-431000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
23000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-239000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-257000
us-gaap Share Based Compensation
ShareBasedCompensation
4075000
us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
2000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
155000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3666000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7521000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1513000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-304000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
122000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
146948000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
139427000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-31713000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
551000
ziop Issuance Of Common Stock In Connection With License Agreement
IssuanceOfCommonStockInConnectionWithLicenseAgreement
87000
ziop Change In Research And Development Expenses
ChangeInResearchAndDevelopmentExpenses
1700000
ziop Research And Development Service Agreement Quarterly Payment
ResearchAndDevelopmentServiceAgreementQuarterlyPayment
3800000
ziop Research And Development Service Agreement Aggregate Payment
ResearchAndDevelopmentServiceAgreementAggregatePayment
18800000
ziop Restricted Stock Buy Back At Vesting To Cover Taxes Value
RestrictedStockBuyBackAtVestingToCoverTaxesValue
853000
ziop Preferred Stock Obligation In Connection With License Agreement
PreferredStockObligationInConnectionWithLicenseAgreement
119045000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M2D
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0169 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.85
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
128413417 shares
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8557 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1800 shares
CY2015Q2 us-gaap Contracts Revenue
ContractsRevenue
272000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14225000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-14211000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14000
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3485000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7073000
CY2015Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14497000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7424000
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8081 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8070 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0138 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.91
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130385077 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0154 pure
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.01
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
116000 shares
CY2016Q2 us-gaap Contracts Revenue
ContractsRevenue
1697000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-131242000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-131200000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42000
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2066000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3711000
CY2016Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
132939000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
129228000

Files In Submission

Name View Source Status
0001193125-16-676724-index-headers.html Edgar Link pending
0001193125-16-676724-index.html Edgar Link pending
0001193125-16-676724.txt Edgar Link pending
0001193125-16-676724-xbrl.zip Edgar Link pending
d226999d10q.htm Edgar Link pending
d226999dex311.htm Edgar Link pending
d226999dex312.htm Edgar Link pending
d226999dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g226999txpg32.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20160630.xml Edgar Link completed
ziop-20160630.xsd Edgar Link pending
ziop-20160630_cal.xml Edgar Link unprocessable
ziop-20160630_def.xml Edgar Link unprocessable
ziop-20160630_lab.xml Edgar Link unprocessable
ziop-20160630_pre.xml Edgar Link unprocessable